Navigation Links
Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
Date:6/6/2008

NEW YORK, June 6 /PRNewswire-FirstCall/ -- Nephros, Inc. (Amex: NEP), a medical device company, announced today that it has completed the pivotal U.S. clinical trial for its OLpur(TM) H2H module and OLpur(TM) MD220 filter for End Stage Renal Disease (ESRD) therapy.

"We're excited and pleased to have reached this important milestone. There is a broad range of literature supporting the advantages of hemodiafiltration (HDF) over dialysis for the ESRD patient, including studies supporting a substantial reduction in the relative risk of mortality. While HDF is prevalent in Europe, no on-line HDF system has yet been approved for use in the U.S. We believe our mid-dilution HDF technology can offer a vital advance in therapy to U.S. ESRD patients," said Norman Barta, Nephros' CEO.

Nephros is now in the process of preparing its submission to the Food and Drug Administration under section 510(k) of the Food, Drug and Cosmetics Act to obtain approval to sell its mid-dilution HDF products in the U.S. If timely approved, Nephros believes its products will be the first on-line HDF products available to ESRD clinics and patients in the U.S.

About Nephros, Inc.

Nephros, Inc., headquartered in New York, is a medical device company developing and marketing products in End Stage Renal Disease (ESRD) therapy and water ultrafiltration.

ESRD is a disease state characterized by the irreversible loss of kidney function. Nephros' HDF products are designed to improve the quality of life for the ESRD patient, while addressing the critical financial and clinical needs of the care provider. The OLpur(TM) H2H is an add-on module that allows the most common types of hemodialysis machines to be used for on-line HDF therapy. The OLpur(TM) MD220 filter employs our proprietary Mid-Dilution diafiltration technology and is sold and distributed throughout Europe. The Nephros HDF system removes a range of harmful substances more effectively than existing ESRD treatment methods, particularly with respect to substances known collectively as "middle molecules." These molecules have been found to contribute to such conditions as dialysis-related amyloidosis, carpal tunnel syndrome, degenerative bone disease and, ultimately, mortality in the ESRD patient.

The Nephros line of water-filtration products incorporates its patented cold sterilization filtration technology, the Dual Stage Ultrafilter (DSU). The DSU has the capability to filter out bacteria, parasites, viruses and other biotoxins to produce biologically safe water, and its dual-stage design reduces the risk and facilitates detection of filter failure. With initial applications targeted at infection-control and potable water solutions, the DSU is in a pilot-use program at a major U.S. medical center and has been selected for further development by the U.S. Marine Corps.

For more information on Nephros, please visit Nephros' website at http://www.nephros.com.

Forward-Looking Statements

Statements in this news release that are not historical facts constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such statements may be preceded by words such as "may," "plans," "expects," "believes," "hopes," "potential" or similar words. For such statements, Nephros claims the protection of the PSLRA.

Forward-looking statements are not guarantees of future performance, are based on assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond Nephros's control. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that Nephros may not be able: (i) to obtain funding if and when needed or on favorable terms; (ii) to continue as a going concern; (iii) to liquidate its short-term investments when needed to fund its operations; (iv) to maintain compliance with the AMEX's continued listing standards; (v) to demonstrate in pre-clinical or clinical trials the anticipated efficacy, safety or cost savings of products that appeared promising to Nephros in research or clinical trials; (vi) to obtain appropriate or necessary governmental approvals to achieve its business plan or effectively market its products; (vii) to have its technologies and products accepted in current or future target markets; or (viii) to secure or enforce adequate legal protection, including patent protection, for its products. More detailed information about Nephros and the risk factors that may affect the realization of forward-looking statements is set forth in Nephros' filings with the SEC, including Nephros' Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007, and Nephros' Quarterly Report on Form 10-Q for the period ended March 31, 2008. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Nephros does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.


'/>"/>
SOURCE Nephros, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
2. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
3. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
4. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
5. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
6. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
7. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
8. VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
9. PacificGMP Completes GMP Product Fill for Trius Therapeutics
10. Cardinal Health Completes Enturia Acquisition
11. DaVita Clinical Research Completes Record Number of Renal Trials in 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2017)... Therapix Biosciences Ltd. (Nasdaq: TRPX), a ... development of cannabinoid-based drugs, today announced that the ... three upcoming scientific and investor conferences in June: ... ... Wednesday, June 7 ...
(Date:5/26/2017)... 2017  Endo International plc (NASDAQ: ENDP ) ... will represent the Company in a fireside chat at Goldman ... June 13, 2017 at 10:40 a.m. PT / 1:40 p.m. ... Rancho Palos Verdes, CA. ... be available on the Company,s website at http://www.endo.com/investors/overview . ...
(Date:5/24/2017)... HAMPTON, Va. , May 24, 2017 /PRNewswire/ ... ivWatch Original Equipment Manufacturer (OEM) Board to enable ... technology with patient monitoring systems, infusion pumps and ... products, OEMs will be able to help health ... care and reduced risks related to IV therapy. ...
Breaking Medicine Technology:
(Date:6/26/2017)... Bethesda, Md (PRWEB) , ... June 26, 2017 ... ... largest orthopaedic group in the country, today announced the hiring of Richard Robinson ... years of diverse leadership and operations experience, with a proven track record of ...
(Date:6/26/2017)... ... June 26, 2017 , ... LARKR™ , an innovative new smartphone app ... across the country to join its online treatment platform. , Launching in just ... a substantially greater number of people in need nationwide, and to supplement their traditional ...
(Date:6/26/2017)... ... ... New patients with missing teeth in Fitchburg, WI, can now ... Cotey is a trusted dentist who has placed many dental implants and enjoys teaching ... teeth in Fitchburg, WI, are encouraged to find out if they are candidates for ...
(Date:6/25/2017)... ... June 25, 2017 , ... Republicans in the United States Senate on ... the Better Care Reconciliation Act. It differs significantly from the American Health Care Act, ... reconciled in committee, or the House will have to take up the Senate version ...
(Date:6/25/2017)... ... ... heatwave currently bearing down on Northern California pushing temperatures to the maximum, many people are ... with laser hair removal. , The process of summer waxing and constantly shaving unwanted ... want to do is get out, dive in and cool off. There is a way ...
Breaking Medicine News(10 mins):